共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
Laurence Klotz 《Current urology reports》2010,11(3):165-171
Active surveillance is a solution to the widely acknowledged problem of overdiagnosis and overtreatment of clinically insignificant
disease which accompanies early detection of prostate cancer using prostate-specific antigen (PSA) and biopsy. It is an approach
to the management of favorable-risk prostate cancer which uses the opportunity provided by the long natural history of the
disease to incorporate a period of initial observation into patient management. The basic concept is that most men diagnosed
with low-grade, small-volume disease are not destined to have any clinical manifestations of the condition during their lifetime.
However, a subset of patients with favorable-risk prostate cancer is at risk, due to either the presence of higher-risk disease
not apparent at diagnosis or progression to a more aggressive phenotype over time. These patients can be identified with reasonable
accuracy by close follow-up, including serial PSAs and biopsies, and treated effectively in most cases. The rationale, patient
selection, method of follow-up, triggers for intervention, and recent results of this approach will be reviewed. 相似文献
11.
12.
13.
《European urology》2020,77(6):675-682
BackgroundActive surveillance (AS) is the preferred management option for most men with grade group (GG) 1 prostate cancer (PCa). Questions persist regarding long-term outcomes and the optimal approach to AS.ObjectiveTo determine survival and metastatic outcomes in AS patients. Secondary objectives were to measure the cumulative incidence and association of patient-level factors on biopsy grade reclassification.Design, setting, and participantsA prospective, active, open-enrollment cohort study was conducted from 1995 through July 2018 at a tertiary-care academic institution. Patients with very-low-risk or low-risk PCa were enrolled.InterventionAS with semiannual prostate-specific antigen (PSA) and digital rectal examination, serial prostate biopsy, and multiparametric magnetic resonance imaging (mpMRI).Outcome measurements and statistical analysisThe 10- and 15-yr cumulative incidences of primary and secondary outcomes were determined.Results and limitationsOverall, 1818 men were monitored on AS for a median of 5.0 yr (interquartile range 2.0–9.0). There were 88 non-PCa deaths, four PCa deaths, and one additional case of metastasis. The cumulative incidence of PCa-specific mortality or metastasis was 0.1% (95% confidence interval, 0.04–0.6%) at both 10 and 15 yr. The 5-, 10-, and 15-yr cumulative incidences of biopsy grade reclassification were 21%, 30%, and 32%, respectively. On multivariable analysis, biopsy grade reclassification was associated with older age, African-American race, PSA density, and increased cancer volume on biopsy, and men who underwent mpMRI prior to enrollment were less likely to undergo grade reclassification. Our selection and monitoring are more stringent than many other contemporary AS programs.ConclusionsIn a large, single-institution, prospective AS cohort, the risk of cancer death or metastasis was <1% over long-term follow-up. Consistent with clinical guidelines, these data support the use of AS for the management of most men diagnosed with GG1 PCa.Patient summaryThis study investigated long-term outcomes in patients with grade group 1 prostate cancer managed with active surveillance (AS). Ten years after enrolling in AS, the risk of metastasis or death from prostate cancer was <1%, while 48% of men switched to treatment. Patients who underwent multiparametric magnetic resonance imaging (mpMRI)/ultrasound-fusion targeted biopsy prior to enrollment were less likely to experience biopsy grade reclassification during follow-up, suggesting a role for mpMRI as part of a comprehensive risk assessment to confirm AS eligibility. These findings support the safety of AS in most men with grade group 1 prostate cancer, but specific outcomes may differ in programs with less intensive monitoring. 相似文献
14.
15.
16.
17.
Laurence Klotz 《The Journal of urology》2009,182(6):2565-2566
18.
19.